SmartECG service supports GPs in diagnosing patients

SmartECG is a service for GPs and healthcare units that supports GPs in diagnosing heart patients. SmartECG willl be ready for full scale market introduction in 2018.

An automatic report within minutes

SmartECG service provides the GP with an automatic ECG analysis report within minutes from downloading the ECG data from ECG monitoring device to SmartECG service.

For patients secondary care diagnosis in primary care level

Earlier detection of heart problems can lead to better treatment results, better quality of live life and even more lives saved.

Faster and more cost-effective healthcare

SmartECG service is a fast and cost-effective way of screening and referring the right patients to secondary care, as well as monitoring diagnosed heart patients during recovery and illness in the primary care level.

  • Early detection of heart diseases can lead to lower treatment costs.
  • Healthcare expertise and costs can be scaled better.
  • The SmartECG service is a low-cost service.



Press release 7.3.2017

Lehdistötiedote 7.3.2017

CardioVascular Diseases a serious health problem in Europe and globally.




Flexible integration to healthcare processes

You can choose how to integrate SmartECG service in your pathways to diagnosis. There are several optional diagnosis pathways that SmartECG service can be integrated to:

      • GP makes the diagnosis him/herself with the support of SmartECG automatic analysis report.
      • GP chooses to request a SmartECG specialist’s consultation report and receives it on average two days from downloading the ECG data. Our service provides a simple and secure telemedicine service platform for fast specialist consultations.
      • GP chooses an internal specialist’s consultation. Data is sent automatically to the internal specialist for an analysis

This is how it works:

SmartECG ready for launch in 2018

The first universal and automated interpretation solution for cardiac data to be launched in 2018

SmartECG service will be a unique and revolutionary solution, an algorithm and service platform with which ECG data can be automatically analysed and interpreted.

80 % compatibility with ECG monitoring devices

SmartECG is the first and only automatic clinical decision support solution that will be compatible with 80 % of different ECG-monitoring devices and suitable for primary and secondary care professionals.

  • SmartECG service will be compatible with 80 % of ECG monitoring devices such as rest and event monitoring devices.
  • By 2020 SmartECG service will analyse ECG data from any ECG monitoring device.
  • The healthcare clinic will be able to apply SmartECG service to the existing ECG monitoring devices.
  • The healthcare clinics will be able to use the ECG monitoring devices more efficiently to monitor more patients.
  • In the piloting phase in 2018 SmartECG service will provide automatic analysis reports from  Holter monitoring devices

SmartECG service will be a medically validated tool for healthcare

The validation process will begin in spring 2018 and we expect to finalize the CE marking process and to receive FDA clearance by 11/2018.

Easy-to-use service model

RemoteA has over 15 years of experience in running a Remote Diagnostic Service Platform, operated today in over 300 healthcare units in Finland, Sweden and United Kingdom. Over 70.000 ECG consultation reports has been delivered thus producing +1.5 million hours of cardiac data to develop the automatic analysis on. RemoteA has developed strong algorithm expertise on ECG data as welll as a wide network of cardiologists, tech and business experts.

Read our story from sleep apnoea monitoring to algorithm-based diagnostics

Från sömnapnémätning till algoritmbaserad diagnostik




Our goal is to Integrate SmartECG to EU healthcare systems by 2022 and globally.

  • 10.000 end-users a.k.a. GPs by 2020
  • We seek to achieve 10-12 % market uptake by 2020, corresponding to €19.2 million annual revenue.

SmartECG service benefits the healthcare ecosystem

SmartECG healthcare

For patients:

Faster diagnosis, better treatment and potentially millions of saved lives

For patients SmartECG means faster diagnosis and better treatment of cardiovascular diseases. Today, it is common that GP’s will limit the number of patients they refer to the tests since they know that the waiting lists are too long already (suppressed demand).

More on effects on patients.

For primary care physicians:

Better decision-making tools

The SmartECG is expected to increase primary care level specialists’ competencies in early ECG diagnosing and for requesting more specific consultations from specialist physicians.

More on effects on primary care physicians.

For specialist physicians:

Concentrate in patients in need of treatment

SmartECG automatic data analysis and pre-selection can reduce the total data amount by 99% and present physicians only the most relevant bits of analysis data. This enables to perform 2-3 times longer and more detailed ECG analysis

More effects on specialists

For healthcare organisations:

Reduced waiting lists

Based on our private studies using data from Finland (2013), about 70% of long-term ECG consultation reports do not recommend secondary care studies and they can be avoided by more competent primary care analysis. This will reduce healthcare waiting lists, avoid duplicating analysis and lower the treatment cost per patient. It is expected that by 2020, around 46% of long ECG analysis are done at primary care level.

More in effects for healthcare organisations.

For consulting specialists:

Possibility for remote work

The consulting specialists that provide primary care physicians the cardiac consultations needed, will be paid for per each remote consultation, depending on their set cost and rewarded either monthly or quarterly, depending on the number of their completed consultations.

For device manufacturers:

Make your ECG monitoring devices more valuable to your customers

Our goal is to create automatic plug-and-play compatibility for 80% of ECG analysis equipment in primary care level and achieve full compatibility with most eHealth systems in targeted countries by 2020.

More on effects on device manufacturers



Why is SmartECG developed

Cardiovascular Disease poses a serious health problem in the EU area and also globally.

  • Almost 10 % of EU population is affected by CVD.
  • In total almost 49 million people have been diagnosed in EU.
  • In total over 85 million people have been diagnosed in Europe.
  • In EU over 6 million people were diagnosed with CVD in 2015.
  • In Europe over 11 million people were diagnosed with CVD in 2015.
  • CVD is the number one cause of death in most European countries.
  • CVD or CVD-related diseases account for 37 % of deaths in EU (1.8 million people annually) and 45 % of deaths in Europe (3.9 million people annully)
  • Early deaths (under 75 years old): In EU over 400.000 early deaths meaning 26 % of all early deaths, stroke-related deaths account for 59 % of deaths.
  • In Europe over 1.3 million meaning 35 % of all early deaths. Stroke-related deaths account for 51 % of deaths and ischemic heart disease for 49 %.
  • Total CVD costs were 110 billion euros in EU countries 110 billion euros (2015).
  • Costs per capita is EU €218
  • Of CVD costs 51 % is spent in inpatient care and 9 % in primary care.
  • Interpreting the ECG analysis results causes a bottleneck in the primary care level as GPs are not equipped to interpret first ECG analysis results by themselves, and in the secondary care level, as specialist cardiologists are facing a huge data and work overload.
  • In Finland CVD is the fourth most general reason to visit doctor’s appointment (after musculoskeletal and respiratory diseases). It also causes multiple visits: there were on average 5 visits per person to nurse appointment due to palpitations *
  • Today 8 million tests performed annually, estimated to grow to 11 million analyses by 2020 (due to advancements in patient-friendly analysis tools and increased number of CVD patients). ECG management systems market will grow to €180 million by 2020. **

Source: European Cardiovascular Disease Statistics 2017 by the European Heart Network

Source *: National Institute for Health and Welfare in Finland

Source ** IHS Report: World Market for Telehealth 2014

One person in ten affected by CVD

One person in ten affected by cardiovascular diseases in UK

Cardiovascular diseases a serious health problem in Europe and globally

En person av nio drabbas av hjärt-kärlsjukdomar i Sverige




The direct impacts and their related effects from SmartECG are:

  1. Better treatment of cardiovascular diseases

  • More accurate and faster diagnosis by more comprehensive and detailed ECG analysis
  • Lower mortality rate and increased life-expectancy of CVD patients
  1. Increased patient-friendliness

  • Reduced healthcare waiting times, increased accessibility to specialist care
  • Wider implementation of remote (home-) monitoring practices
  • Reduced travel costs and time
  1. Higher medical professionality

  • Empowered primary and secondary care specialists in CVD diagnosing and monitoring
  • Increased collaboration and sharing practices between GPs and specialist physicians
  1. More efficient healthcare system

  • Improved and more competent primary care level
  • Shorter waiting lists, increased patients throughput
  • Lower cost per patient and reduced CVD treatment expenditures
  • Increased international cooperation and free movement of healthcare services in EU
  • Standardised ECG analysis output for best compatibility with various eHealth solutions

Contact us

We are happy to tell you more about SmartECG service

Please contact:

Mr. Heikki Väänänen, Head of Anaytics, heikki.vaananen(at), tel. +358 50 586 7460

Ms. Hannele Pulliainen, Marketing Manager, hannele.pulliainen(at), tel. +358 44 355 5225

Pre-release! Join our SmartECG Panel for Healthcare Professionals

Our goal is to provide the best possible decision-making tool for the GPs and other healthcare professionals. In order to reach that goal we kindly ask for your help to develop the Superior SmartECG Service Experience. Join the SmartECG Panel for Healthcare Professionals, share with us your needs, insight and experiences and help us develop the Superior SmartECG Service Experience.

How does the SmartECG Panel for Healthcare Professionals work?

You will receive every other month on average a link to a short survey. The survey topics will cover for example User Interface testing, automatic analysis report structure and content etc.

When will SmartECG Panel start?

Our goal is to lauch the panel in November 2017.

Will the SmartECG Panel be in English?

The Panel will be available in three languages: Finnish, Swedish and English.

How can I join the SmartECG Panel?

Please leave your contact information

Interested in regular updates?

Please subcsribe to our newsletter here, and we will keep you posted by sending newsletters a couple of times during the year.

SmartECG is co-funded by the Horizon 2020 programme that helps high-potential SMEs to develop groundbreaking innovative ideas for products, services or processes that are ready to face global market competition.

RemoteA Ltd. was one of the four ICT companies to receive funding of the total 104 ICT companies applying for it, and RemoteA Ltd. also received the highest scores.